Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins
- PMID: 23861639
- PMCID: PMC3663607
- DOI: 10.4137/JCNSD.S5018
Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder. Currently available therapies are symptomatic but do not alter underlying disease progression. Immunotherapeutic approaches such as anti Aβ peptide active vaccination trials have had limited success to date. Intravenous immunoblobulin (IVIg) is widely used in immune-mediated neurological disorders such myasthenia gravis and Guillain-Barre syndrome. These preparations have been obtained from the pooled plasma of healthy human donors and contain natural anti-amyloid antibodies and are well tolerated. A small pilot study of passive immunotherapy using IVIg has suggested cognitive improvement. A multicenter phase III trial is ongoing and will determine whether or not this treatment can ameliorate cognitive deficits in mild-to-moderate AD. Here, we briefly review the pathogenic role of amyloid and tau in AD, as well as immunotherapeutic efforts to date. We also summarize what is known about naturally occurring anti-Aβ and tau antibodies in IVIg with a view toward explaining potential mechanisms underlying their therapeutic effects.
Keywords: Alzheimer’s; amyloid oligomers; conformation antibodies; immunotherapy; tau oligomers.
Similar articles
-
Intravenous immunoglobulins for Alzheimer's disease.Curr Alzheimer Res. 2014;11(7):626-36. doi: 10.2174/1567205011666140812113415. Curr Alzheimer Res. 2014. PMID: 25115546 Review.
-
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Immunotherapy. 2012. PMID: 22339463 Review.
-
Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations.Degener Neurol Neuromuscul Dis. 2014 Sep 5;4:121-130. doi: 10.2147/DNND.S51786. eCollection 2014. Degener Neurol Neuromuscul Dis. 2014. PMID: 32669906 Free PMC article. Review.
-
Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.Drugs. 2010 Mar 26;70(5):513-28. doi: 10.2165/11533070-000000000-00000. Drugs. 2010. PMID: 20329802 Review.
-
Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.J Neurochem. 2013 Aug;126(4):473-82. doi: 10.1111/jnc.12305. Epub 2013 Jun 16. J Neurochem. 2013. PMID: 23672786 Free PMC article.
Cited by
-
Natural antibodies - facts known and unknown.Cent Eur J Immunol. 2018;43(4):466-475. doi: 10.5114/ceji.2018.81354. Epub 2018 Dec 31. Cent Eur J Immunol. 2018. PMID: 30799995 Free PMC article. Review.
-
A Special Connection between γδ T Cells and Natural Antibodies?Arch Immunol Ther Exp (Warsz). 2016 Dec;64(6):455-462. doi: 10.1007/s00005-016-0403-0. Epub 2016 May 27. Arch Immunol Ther Exp (Warsz). 2016. PMID: 27235134 Free PMC article. Review.
-
Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases.Mol Neurodegener. 2017 Oct 23;12(1):75. doi: 10.1186/s13024-017-0218-4. Mol Neurodegener. 2017. PMID: 29061112 Free PMC article. Review.
-
Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics.Proteins. 2025 Aug;93(8):1314-1329. doi: 10.1002/prot.26561. Epub 2023 Aug 2. Proteins. 2025. PMID: 37530227 Free PMC article. Review.
References
-
- Editorial. How much is dementia care worth? The Lancet Neurology. 2010;9:1037. - PubMed
-
- Selkoe DJ. Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev. 2001;81:741–66. - PubMed
-
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6. - PubMed
-
- Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer’s disease. Biomed Pharmacother. 2008;62:199–207. - PubMed
LinkOut - more resources
Full Text Sources